Septins are an evolutionarily conserved family of GTPases with diverse functions including roles in cytokinesis that have been implicated in neoplasia. To address the potential role of SEPT9 in tumorigenesis, we assessed the expression of SEPT9 in 7287 fresh frozen human tissue samples and 292 human cell lines by microarray analysis. In addition, we used a sensitive RT-PCR strategy to define the expression of SEPT9 isoforms in archival formalin-fixed and paraffin-embedded normal human tissues. The mRNA data were further confirmed by immunohistological analyses of SEPT9 protein expression in normal human tissues using antisera that detect SEPT9 isoforms. Using these complementary approaches, we demonstrate that SEPT9 mRNA and protein are expressed ubiquitously, with the isoforms showing tissue-specific expression. The microarray analysis indicates that there is consistent overexpression of SEPT9 in diverse human tumours including breast, CNS, endometrium, kidney, liver, lung, lymphoid, oesophagus, ovary, pancreas, skin, soft tissue and thyroid. Since tumours are commonly associated with enhanced cell proliferation, we examined the possible correlation of Ki67 and SEPT9 expression in normal tissues and tumours. Our data indicate that the overexpression of SEPT9 in neoplasia is not simply a proliferationassociated phenomenon, despite its role in cytokinesis.
Introduction
The septin gene family encodes cytoplasmic GTP binding and hydrolysing proteins which may form filamentous complexes and are involved in diverse cellular processes including cytokinesis, vesicle trafficking, apoptosis and maintenance of cell polarity . The mechanistic basis for the pleiotropic properties of the septins remains obscure although they may form scaffolds of homo-and heterooligomers to facilitate signalling or other events (Field and Kellogg, 1999; Hall and Russell, 2004; Martinez et al., 2004) . The family of 12 human septins shows considerable homology in the core GTP-binding domain (Leipe et al., 2002) , but divergence in the N and C termini . While most of the available data relate to the biology and biochemistry of septins in model organisms, and in particular in yeast (Faty et al., 2002) , several lines of evidence suggest a role for septins in the development of neoplasia (Kartmann and Roth, 2001; Hall and Russell, 2004) . A number of septin genes (SEPT5, SEPT6, SEPT9 and SEPT11) are involved in chromosomal translocations in acute myeloid leukaemia with the formation of chimeric MLL fusion proteins (Osaka et al., 1999; Hall and Russell, 2004) . Oncogenic retroviral insertions occur in the 5 0 end of the mouse orthologue of SEPT9 in models of murine T-cell lymphoma (Srensen et al., 2000) . We have shown that SEPT9 maps to a region of allelic imbalance on chromosome 17q25.3 in sporadic epithelial ovarian tumours (Russell et al., 2000; McIlhatton et al., 2001) and SEPT9 was independently identified as a region of allelic imbalance in sporadic breast cancer . Although mutations have not been reported in the open reading frame, abnormalities of SEPT9 expression have been reported in ovarian cancer (Burrows et al., 2003; Robertson et al., 2004) with evidence of altered SEPT9 promoter methylation (Russell et al., 2000) . Furthermore, Montagna et al. (2003) have shown that SEPT9 is amplified and overexpressed in murine models of breast cancer and in six of nine human breast cancer cell lines.
Such data emphasize the need to understand septin biology, which is complicated by not only the number of septin genes but also the existence of multiple splice variants. For example, alternative splicing of the 17 exons of SEPT9 (spread over a 250 kB region of chromosome 17q25.3) generates six mRNA species with different 5 0 termini (designated SEPT9_v1, v2, v3, v4, v4* and v5) (Figure 1a) . Moreover, nonconsensus intraexonic splicing generates three possible 3 0 mRNA ends (designated 'a', 'b' and 'c') such that splice variants 'b' and 'c' access a short open reading frame at the end of exon 12 . It has been shown that alterations in the transcript profile of SEPT9 occur with changes in the ratio of SEPT9_v4 and SEPT9_v4* mRNAs in normal and neoplastic cells (Burrows et al., 2003) . Intriguingly, these distinct mRNA species with very different 5 0 UTRs encode exactly the same polypeptide, an observation suggesting a role for translational control in SEPT9 expression. With this background, we have undertaken a comprehensive review of SEPT9 expression in human tissue using different modalities including cDNA microarray, RT-PCR and protein analysis by isoformspecific immunohistochemistry. These complimentary approaches have generated multiple data sets which provide cross-validation for the methods employed and insight into the patterns of SEPT9 expression in human tissues. Furthermore, we demonstrate altered expression of SEPT9 in diverse human tumour types and show that this altered expression is not simply a proliferationassociated phenomenon.
Results

Microarray data
The microarray data using probe sets 41220_at, 208657_s_at and 207425_s_at represent all SEPT9 transcripts including all known 5 0 and 3 0 variants. The arbitrary signal intensity for each sample from a given anatomical site is plotted on a linear scale with median and interquartile ranges shown, and subdivided into normal (green), diseased (blue) and tumour (red) categories. Examination of the electronic Northern plots for these probesets (Figure 2a-c) indicates that SEPT9 mRNA is detectable in all tissue types examined, albeit at varying levels. Highest expression is found in lymphoid compartments including lymph nodes, spleen, thymus and white blood cells (WBC). The electronic Northern plots are similar although not identical, with slight differences in, for example, the thymus. The complexity of the probe set distribution (see Figure 1b) presumably accounts for such differences. Nevertheless, the broad similarity suggests that the three 3 0 variants have similar patterns of expression. All subsequent analyses are based on 41220_at, which can be considered a pan SEPT9 probe.
SEPT9 mRNA expression was examined in a large cohort of samples defined by anatomical site and divided into normal, non-tumour diseased and tumour categories (n ¼ 5884; Table 1 ). A striking feature is that in diverse tissues (breast, CNS, endometrium, oesophagus, kidney, liver, lung, lymphoid, ovary, pancreas, skin and thyroid), the median level of expression of SEPT9 mRNA is significantly higher in malignant tumours than in normal tissues (Table 1 ). In kidney, median SEPT9 expression in malignant tumours is 2.7-fold higher than in normal tissue (1194 vs 429.8; Po0.001, Dunn multiple comparison test). Similarly, SEPT9 expression is 2.8-fold higher in pancreatic tumours and 2.12-fold higher in thyroid tumours compared with normal tissues. Given the high expression in the lymphoid compartment, we specifically investigated expression in lymphocytes and other white cell subsets prepared by FACS (n ¼ 231, Figure 3 ). SEPT9 is expressed in all populations but is highest in T-cells and dendritic reticulum cells (DRC) and lowest in neutrophils. There is increased expression of SEPT9 in lymphomas (Table 1) but no significant difference is seen between expression in neutrophils and myeloid leukemias (n ¼ 6, Figure 3 ) or between thymic neoplasms (thymoma, n ¼ 4, Table 1 ) and normal thymus.
Electronic Northern plot analysis of Ki67 (Figure 2d ), a well-validated marker of cell proliferation (Hall and Levison, 1990; Whitfield et al., 2002) , shows elevated expression in tumours. Table 1 indicates that Ki67 signal broadly parallels that of SEPT9 with upregulation in many tumour types. This could suggest that SEPT9 expression is associated with a proliferationassociated cellular process given that septins are implicated in cytokinesis . However, we did not observe a strong relationship between signal intensity from the Ki67 and SEPT9 probe sets. In all tissues examined, Spearman correlation coefficients showed only weak correlations exemplified by breast (r ¼ 0.2249, Po0.0001), CNS (r ¼ 0.06988, P ¼ 0.0326) and lymphoid (r ¼ 0.3513, Po0.0001) (Figure 4) . 
Validation of DNA microarray by RT-PCR
A stringent RNA extraction method coupled with intron-spanning PCR primer pairs capable of generating small amplicons (o100 base pairs) allows RT-PCR expression profiling for low-abundance mRNAs such as SEPT9 in archival formalin-fixed paraffin-embedded tissues. The approach was first validated in control cell line-derived mRNA (Figure 5a ). Figure 5b illustrates a qualitative analysis of SEPT9 5 0 splice variants in a panel of normal human tissues. There is agreement between the microarray data from normal tissues and RT-PCR analysis since SEPT9 transcripts are ubiquitous albeit with varying levels of signal intensity. In addition, there are differences in the expression profile of the different 5 0 isoforms of SEPT9. Laser microdissection allowed assessment of the SEPT9 mRNA profile in enriched epithelial and stromal cell populations in normal (cervix; Figure 5c ) and neoplastic (ovarian serous carcinoma; Figure 5d ) tissues. Although not all transcripts are detectable by single-round amplification, qualitative RT-PCR of quantity-matched epithelial and stromal cell dissectates (20 million mm 3 ) demonstrates that SEPT9_v1 mRNA is consistently more readily detectable in epithelia than stroma (by comparison to b-actin).
Validation of expression by immunohistochemistry
The immunological characterization of SEPT9 protein isoforms is complicated by their relative similarity. SEPT9_v1, v2 and v3 differ only by 25, 18 and 7 residues at the N-terminus, respectively ( Figure 6 ). SEPT9_v4 is an N-terminal truncated form of 
SEPT9_v1, v2 and v3; SEPT9_v5 represents a further N-terminal truncation of SEPT9_v4. In Western blots of SEPT9 proteins expressed in coupled in vitro transcription/translation reactions, serum S9-13 recognizes all SEPT9 isoforms except SEPT9_v5, while S9-5 recognizes SEPT9_v1 (and v2 and v3) but not SEPT9_v4 or v5 (Figure 7 ). In contrast, serum S9-1 (raised to peptides within SEPT9_v5) recognizes all SEPT9 isoforms. Examination of Western blots of cell lysates indicates the expected pattern of SEPT9 reactivity, patterns which are not seen with preimmune serum. Therefore, S9-5, S9-13 and S9-1 are SEPT9-specific reagents, which facilitate the distinction of SEPT9_v5 (S9-1 only), v4 (S9-1 and S9-13) and v1, v2 and v3 (S9-1, S9-13 and S9-5). All three sera show similar staining patterns in tissues, patterns not seen with preimmune serum or by preincubation with immunogen. Cytoplasmic immunoreactivity is present in all cell types in each tissue examined although the intensity of staining varies (Figure 7 ). This is in accordance with the microarray data and the RT-PCR observations described above. To gain more insight into this variation, we undertook studies using the sera at a broad range of antibody dilutions since a higher level of antigen is required for a given signal as antibody dilution increases (McCormick et al., 1993) . We find that epithelium has consistently higher levels of SEPT9 immunoreactivity than associated stroma, consistent with the RT-PCR observations. Another point of note is the association of enhanced staining at membrane aspects of epithelia and in particular with their secretory pole (e.g. gastric pits, salivary gland, endocervix) and in highly secretory cells such as plasma cells. Only in one context was noncytoplasmic staining seen, namely the cells of the seminiferous tubule. Here we observed strong nuclear staining in the meiotic populations with S9-13 but not with S9-1 or S9-5. This presumably reflects a crossreaction to an as yet unidentified antigen since we would expect immunoreactivity with S9-1 if it were genuine SEPT9 immunoreactivity. Although unlikely, we cannot exclude the phenomenon of epitope masking in a novel meiosis-associated nuclear form of SEPT9 and a bipartite nuclear localization signal does exist in the N-terminus of SEPT9_v1.
Discussion
While originally viewed as genes whose products were involved in cytokinesis, considerable data now indicate that in yeast septins have roles in determining cell polarity and can have effects on cell membranes, the bactin and tubulin cytoskeletons and functions in vesicle trafficking (Kartmann and Roth, 2001; Hall and Russell, 2004) . The complexity of septins is underscored by both the diversity of phenomena in which they have been implicated and the number and complexity of septin genes in man. Several lines of evidence implicate septins, and in particular SEPT9, in neoplasia. For example, although no evidence for somatic (or germline) mutation has yet been presented, several reports indicate alterations in SEPT9 expression in tumours Russell et al., 2000; Srensen et al., 2000; Montagna et al., 2003) including evidence for promoter methylation (Burrows et al., 2003) . Such data suggest that SEPT9 may act as a type II cancer gene (Sager, 1997) where alteration in expression, including alteration in specific protein isoforms, holds the key to understanding a putative role in neoplasia. These observations prompted our studies and here we present data derived from microarray analysis of a substantial sample of human normal and diseased tissues. The microarray data are validated by RT-PCR analysis of mRNA from normal adult human tissues and we also show, using isoform-specific antisera, that SEPT9 protein is widely expressed. These data sets are congruent and together provide evidence that SEPT9 is overexpressed in diverse human tumours, albeit at modest levels. However, the statistical power derived from the size of the data sets lends veracity to these observations. Important caveats to such data exist. First, the microarray data are based upon an average expression value from the combined cellular compartments in the tissue samples from which the mRNA was extracted. Secondly, this takes no account of the complexity of the isoforms expressed. Our laser microdissection and SEPT9 is over-expressed in neoplasia M Scott et al RT-PCR data indicate clearly that there are spatial differences in the nature of SEPT9 isoforms expressed in different cellular compartments. This is further validated by the spatial information inherent in the immunohistochemical studies. However, the similarity of the data from the three Affymetrix probe sets suggests that, at least by this assay, major differences in the expression of the three potential 3 0 splice variants ('a', 'b' and 'c') are not detectable. Thirdly, despite the power of microarray analysis of large sample series, there is a need to employ RT-PCR and use caution in the interpretation of antibody-based methods as some isoforms cannot be unequivocally identified. For example, the polypeptide SEPT9_v5 is present in all other isoforms (Russell et al., 2000; McIlhatton et al., 2001; Hall and Russell, 2004) and SEPT9_v4 and SEPT9_v4* are distinct mRNAs, but encode identical polypeptides whose expression patterns change in neoplasia (Russell et al., 2000; McIlhatton et al., 2001) . The final caveat is that the data take no account of the full spectrum of septins present in tissues. Recent data indicate that complex regulatory mechanisms exist whereby the levels of one septin can influence expression of other septins (Peng et al., 2002; Kremer and Macara, 2003) .
Notwithstanding these caveats, our data provide a comprehensive expression profile for a human septin in physiological and pathological states. SEPT9 protein expression is ubiquitous although variations in level are seen. However, there is no striking relationship between SEPT9 and proliferative morphologically defined compartments. Furthermore, we find no convincing evidence for any cell cycle-associated variation in expression of SEPT9 mRNA given the weak correlation with Ki67 mRNA expression, an observation consistent with data from microarray analysis of synchronised HeLa cells (Whitfield et al., 2002) . Finally, the ubiquitous expression of SEPT9 in adult tissues should be contrasted with the regulated expression of the murine SEPT9 mRNA in development (Srensen et al., 2002) .
These data taken together suggest that a role for SEPT9 in neoplasia is unlikely to be related to cell proliferation per se, but rather to other cellular processes. In this context we have recently shown that altered levels of SEPT9 can be associated with cell motility (Chacko et al., submitted) . It is of interest that SEPT9 levels are higher in metastatic lesions in many tissues including breast (P ¼ 0.0016), kidney (P ¼ 0.0007), liver (P ¼ 0.0001), pancreas (P ¼ 0.0001), skin (P ¼ 0.0001) and thyroid (P ¼ 0.0001). It is noteworthy that there is an association of SEPT9 immunoreactivity with cell borders and apical aspects of secretory epithelia, consistent with SEPT9 having a role in both polarization and membrane and vesicle trafficking. Moreover, there is growing evidence for membrane dynamics and vesicle trafficking having roles in neoplasia (Polo et al., 2004) : perhaps SEPT9 isoforms modulate such phenomena? It is also noteworthy that lymphoid cell populations have the highest expression of SEPT9 since it is in lymphoid leukaemias that reciprocal translocations have been reported with the N-terminus of MLL linked to almost the entire SEPT9 protein (Osaka et al., 1999) .
The data we present provide a basis for further analysis of SEPT9 and other septins and indicate the complexity of this gene family. We show that microarray analysis of substantial numbers of clinical samples can provide valuable insights into septins, but that the complexity of expression with the existence of many isoforms as a result of alternate splicing coupled with subtle cell type-specific control of expression mean that multimodal approaches are essential for the full characterization of this enigmatic gene family. Future studies will focus on defining the detailed expression of specific isoforms in tumour progression and linking this to functional studies of SEPT9.
Materials and methods
Expression microarray experiments
The Gene Logic s (Gaithersburg, MD, USA) database of Affymetrix s HG-U133 GeneChip s probearray data was screened for probes that corresponded to the SEPT9_v3a and Ki67 mRNA sequences (Genbank Accession numbers NM_006640 and NM_002417, respectively). Probes with the highest proportion of samples called 'present' were chosen for downstream analysis on 7579 samples comprising 7287 fresh frozen human tissue samples and 225 cell lines. Gene Logic performed tissue preparation from validated samples in their biorepository. Diagnoses were further validated by in-house analysis by Pathology at Genentech. cRNA was analysed on the U-133 Genechip in accordance with Affymetrix's protocols. Genechips were scanned using proprietary GeneLogic software with normalization using Affymetrix MAS 5.0 algorithms. For SEPT9 three probes (207425_s_at, 208657_s_at and 41220_at) were identified and three probe sets were excluded (239030_at, 220582_at, 228978_at) since they could not be mapped to known SEPT9 transcripts. Owing to nonconsensus intraexonic splicing in exon 12, the oligomers within probe sets 41220_at, 207425_s_at and 208657_s_at are not fully represented in either the 'b' or 'c' variants. The sequences recognized by 208657_s_at are fully spliced out of the 'b' and 'c' variants (see Figure 1b ) and thus this is specific for SEPT9_vXa (where X is 1, 2, 3, 4 or 5). Two of 11 oligomers from 207425_s_at are lost in the 'b' forms and four of 11 oligomers lost from the 'c' form. Two of 16 oligomers from 41220_at are lost in both 'b' and 'c' forms.
From the 7287 fresh frozen human tissue samples, 1403 were omitted as being diverse leucocyte populations, blood vessel and heart, histologically heterogeneous groups such as head and neck or samples of minor clinical significance such as gall bladder, leaving 5884 samples. Statistical analysis of expression data was carried out using GraphPad Prism s 4 software. Analysis by Kruskal-Wallis test was performed comparing the three GeneExpress database categories (normal, nonmalignant diseased and malignant) in each tissue type. Pairwise comparisons of categories used the Dunn post-test. Spearman correlation coefficient of relevant SEPT9 and Ki67 datasets was also calculated. A significance level of Po0.05 was applied to each analysis.
Tissues, RNA extraction, reverse transcription and PCR
Anonymized formalin-fixed paraffin-embedded tissue blocks were retrieved from the histopathology archives of Belfast SEPT9 is over-expressed in neoplasia M Scott et al Link Laboratories following approval by the Local Research Ethics Committee. In all, 20 5 mm-thick sections were dewaxed, rehydrated and then digested for 20 h at 581C in 2 mg/ml proteinase K (Sigma), 20 mM Tris-HCl (pH 8.0), 20 mM EDTA and 2% SDS. Following heat inactivation of proteinase K, total RNA was extracted by RNA Stat-60; precipitated and the pelleted RNA resuspended in DEPC-treated sterile water and subjected to RQ1 DNase digestion (Promega). In other experiments, epithelial and stromal elements were studied after microdissection of toluidine blue-stained tissue sections using a Leica AS LMD laser microdissection system. The PEO4 cell line was used to provide positive control mRNA (McIlhatton et al., 2001; Burrows et al., 2003) . cDNA was generated by standard methods. Intron-spanning oligonucleotide primer pairs were designed for each SEPT9 5 0 splice variant and a-actin (see Supplementary information). PCR was carried out under standard conditions with an annealing temperature of 551C for all reactions. The identity of each product was confirmed by sequencing of both strands.
Antibody production, characterization and immunohistochemistry
Polyclonal sera were raised to KLH-conjugated peptides using standard methods (Eurogentec, Belgium (Robertson et al., 2004) in in vitro coupled transcription/translation reactions, resolved on polyacrylamide gels, transferred to nitrocellulose filters and probed with relevant immune sera or preimmune control serum. Protein bands were detected by enhanced chemiluminescence as described previously (Robertson et al., 2004) . In other experiments protein lysates were derived from human tumour cell lines and similarly examined. Immunohistochemistry was performed on paraffin sections of normal human tissues using standard methods. In brief, sections were dewaxed, rehydrated and probed with antisera or preimmune controls after blocking of endogenous peroxidase. A range of dilutions were employed during optimization to reflect different levels of antigen expression. Primary antibody was detected by a biotin-free EnVision þ t system (both DakoCytomation, UK) with diaminobenzidine as a chromogen and with haematoxylin counterstain.
